JUFU TANG BIOT (08217) released its annual performance with a net profit of HKD 23.18 million.
Chikufukudo Biotechnology (08217) announced its annual performance for the year ending March 31, 2026, with revenue of HK$37.55 million, an increase of 3.7% compared to the previous year; net profit of HK$23.31 million, compared to a loss of HK$5.99 million in the same period last year; and earnings per share of 7.72 Hong Kong cents.
Ju Fu Tang Biot (08217) announced its annual performance for the year ending March 31, 2026, with a revenue of HK$37.55 million, an increase of 3.7% year-on-year; a net profit of HK$23.31 million, compared to a loss of HK$5.89 million in the same period last year; basic earnings per share of HK$0.0772.
Related Articles
US Stock Market Move | The valuation frenzy is cooling down, SpaceX (SPCX.US) drops more than 7%.
US Stock Market Move | Popular Chinese concept stocks mostly rise. PDD Holdings Inc. Sponsored ADR Class A (PDD.US) surged almost 6%.
US Stock Market Move | Wash said that inflation risks in the United States have decreased, with gold and silver stocks generally rising. Gold Fields Limited Sponsored ADR (GFI.US) rose more than 4%.
US Stock Market Move | The valuation frenzy is cooling down, SpaceX (SPCX.US) drops more than 7%.
US Stock Market Move | Popular Chinese concept stocks mostly rise. PDD Holdings Inc. Sponsored ADR Class A (PDD.US) surged almost 6%.
US Stock Market Move | Wash said that inflation risks in the United States have decreased, with gold and silver stocks generally rising. Gold Fields Limited Sponsored ADR (GFI.US) rose more than 4%.
RECOMMEND
